636 related articles for article (PubMed ID: 29167342)
1. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
[TBL] [Abstract][Full Text] [Related]
2. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.
Wan H; Gao J; Xu K; Chen H; Couzens LK; Rivers KH; Easterbrook JD; Yang K; Zhong L; Rajabi M; Ye J; Sultana I; Wan XF; Liu X; Perez DR; Taubenberger JK; Eichelberger MC
J Virol; 2013 Aug; 87(16):9290-300. PubMed ID: 23785204
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.
Jiang L; Fantoni G; Couzens L; Gao J; Plant E; Ye Z; Eichelberger MC; Wan H
J Virol; 2016 Jan; 90(1):117-28. PubMed ID: 26468531
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.
Wan H; Qi L; Gao J; Couzens LK; Jiang L; Gao Y; Sheng ZM; Fong S; Hahn M; Khurana S; Taubenberger JK; Eichelberger MC
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167344
[TBL] [Abstract][Full Text] [Related]
8. Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
Changsom D; Lerdsamran H; Wiriyarat W; Chakritbudsabong W; Siridechadilok B; Prasertsopon J; Noisumdaeng P; Masamae W; Puthavathana P
PLoS One; 2016; 11(4):e0153183. PubMed ID: 27054879
[TBL] [Abstract][Full Text] [Related]
9. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
[TBL] [Abstract][Full Text] [Related]
10. Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model.
Tan J; O'Dell G; Hernandez MM; Sordillo EM; Kahn Z; Kriti D; van Bakel H; Ellebedy AH; Wilson PC; Simon V; Krammer F; McMahon M
J Virol; 2022 Jan; 96(2):e0142121. PubMed ID: 34669506
[TBL] [Abstract][Full Text] [Related]
11. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus.
Jiang H; Peng W; Qi J; Chai Y; Song H; Bi Y; Rijal P; Wang H; Oladejo BO; Liu J; Shi Y; Gao GF; Townsend AR; Wu Y
mBio; 2020 Oct; 11(5):. PubMed ID: 33024040
[TBL] [Abstract][Full Text] [Related]
13. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
14. Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans.
Rijal P; Wang BB; Tan TK; Schimanski L; Janesch P; Dong T; McCauley JW; Daniels RS; Townsend AR; Huang KA
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748388
[TBL] [Abstract][Full Text] [Related]
15. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
[TBL] [Abstract][Full Text] [Related]
16. Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.
Job ER; Ysenbaert T; Smet A; Van Hecke A; Meuris L; Kleanthous H; Saelens X; Vogel TU
mBio; 2019 Oct; 10(5):. PubMed ID: 31641082
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
[TBL] [Abstract][Full Text] [Related]
18. Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.
Chen YQ; Wohlbold TJ; Zheng NY; Huang M; Huang Y; Neu KE; Lee J; Wan H; Rojas KT; Kirkpatrick E; Henry C; Palm AE; Stamper CT; Lan LY; Topham DJ; Treanor J; Wrammert J; Ahmed R; Eichelberger MC; Georgiou G; Krammer F; Wilson PC
Cell; 2018 Apr; 173(2):417-429.e10. PubMed ID: 29625056
[TBL] [Abstract][Full Text] [Related]
19. An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses.
Shoji Y; Chichester JA; Palmer GA; Farrance CE; Stevens R; Stewart M; Goldschmidt L; Deyde V; Gubareva L; Klimov A; Mett V; Yusibov V
Hum Vaccin; 2011; 7 Suppl():199-204. PubMed ID: 21922687
[TBL] [Abstract][Full Text] [Related]
20. Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.
Changsom D; Jiang L; Lerdsamran H; Iamsirithaworn S; Kitphati R; Pooruk P; Auewarakul P; Puthavathana P
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
